Annovis Bio Inc. (ANVS) is gaining attention as it advances multiple late-stage clinical programs targeting neurodegenerative diseases. With its lead candidate Buntanetap progressing through pivotal trials in Alzheimer's disease (AD) and Parkinson's disease (PD), and a scheduled FDA Type C meeting in January 2026 to discuss the pathway for Parkinson's disease dementia (PDD), the company is positioned for several catalysts that could reshape its outlook in the coming year.
Recent Stock Performance
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.